NEW YORK, Nov. 28 — Silico Insights said Wednesday that it had added three new members to its scientific board of directors, David Schoenfeld , Cathy Wu , and Sudhir Sahasrabudhe .

The company, founded in 2000, is focused on characterizing pathways implicated in cancer.

Sahasrabudhe is executive vice president at Myriad Genetics , and was also a biotechnology chief at Aventis , representing the company for the SNP Consortium .

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.